Prakash Industries: A clarification

On 3rd September, here is what we said in the report regarding steelmaker Prakash Industries, citing research from reputed institutional brokers such as Edelweiss: The company has a 100MW captive power unit. Prakash is also setting up a 625MW power plant. It has been operating a coal mine in Chotia, Chhattisgarh, since 2006. The mine has B grade reserves of about 50 million tonnes (MT) with current extraction of about 1 mtpa.

We did not have any notion of any wrongdoing in this respect. We also reiterate that we have not recommended the stock in any way in this article. The purpose of the article was to throw some light on an otherwise not widely-tracked stock, citing available research.

Here is the clarification put out by Prakash Industries, reproduced verbatim: "The extraction of coal, its quantity, grade and usage are being verified every year by the Office of the Coal Controller, Government of India, State Mining Department and other Government agencies from time to time. After meeting out the coal requirements of Sponge Iron Plant the left out middlings are being used for captive power plant requirements. Company has to buy coal through E-Auction to meet with its requirement for additional expansion in Sponge Iron Plant."



Shibaji Dash

7 years ago

It's heartening indeed the company volunteers such unflattering but true information about itself.Captive power plants may or may not be able to generate quality power. It appears to have become a habit with many journos/analysts to report an enterprise having set up or about to set up a captive power plant for the info of investors without touching upon the likely profit earning capacity of the captive power plant.A CPP can not be equated with an IPP. The company in this case therefore is an exemplar in the given context.

Allergan agrees to pay $600 million for illegally promoting Botox

Allergan has pleaded guilty for its “off-label” promotion of Botox and has agreed to pay $600 million to settle charges in a longstanding federal investigation. But the Botox maker maintains that the drug is safe and says many people have taken it with no problems

Allergan Inc, a multi-specialty healthcare company, has agreed to pay $600 million to settle federal charges for “illegally promoting and selling” Botox through 2005 for “unapproved uses” like treating headaches.

According to, the US Food and Drug Administration (FDA) had approved Botox only for use in rare conditions but the company had vigorously promoted it for “off-label uses”, including relief from headaches, pain, spasticity and juvenile cerebral palsy. Off-label use is the practice of prescribing pharmaceuticals for an unapproved indication.

US attorney Sally Yates has been quoted as saying that Allergan made it a top corporate priority to maximise sales of far more lucrative off-label uses that were not approved by the FDA. Yates further says, “Allergan further demanded tremendous growth in these off-label sales year after year, even when there was little clinical evidence that these uses were effective.”

Botox is designed to block nerve impulses to certain muscles, causing them to relax. The product is approved to treat uncontrolled muscle contractions of the neck and shoulder muscles. Botox is also approved for cosmetic use to treat wrinkles between the eyebrows and to help control excessive underarm sweating.

In some cases, the toxic, active ingredient in Botox — a derivative of botulism toxin Type A, one of the deadliest poisons known — can affect respiratory muscles and cause difficulty in swallowing, a condition known as dysphagia. The product warns doctors and consumers of that side effect.

The FDA said that it appears the active ingredient in Botox can spread from distant parts of the body — such as children’s leg muscles — to muscles that affect breathing.

The company, based in Irvine, California, was named in both civil and criminal complaints filed in the US District Court in Atlanta.

Allergan, on its website, has agreed to plead guilty to a single misdemeanour “misbranding” charge covering the period 2000 through 2005 and pay to the government $375 million. This misbranding charge is known as a strict liability offence. A prescription drug is considered misbranded when its labelling does not contain adequate directions for its “intended uses”.
In addition, Allergan has agreed to pay $225 million to resolve civil claims asserted by the US Department of Justice under the civil False Claims Act. The civil settlement is an element of a global settlement that Allergan believes is in the best interest of its stockholders.

The Botox maker said, “As part of its plea, Allergan has agreed that between 2000 through 2005, its marketing of Botox resulted in intended uses for the therapeutic treatment of headache, pain, spasticity and juvenile cerebral palsy. These uses were off-label during the relevant time frame and thus the labelling for Botox did not bear directions for these intended uses, resulting in the product being misbranded.”

In March 2010, the US FDA approved Botox for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper-limb spasticity. The label now included directions for that use, it added.

Allergan denies liability associated with these civil allegations and does not believe there is merit in them factually or legally, said the company in a statement.

However, if one glances through, a series of cases have been mentioned against the company. The sites states that Botox users are pursuing a class action lawsuit against Allergan, claiming the company failed to adequately warn users of the drug’s dangers. The suit, filed in July 2008, claims the toxin-based drug killed at least three people, including a seven-year-old girl with cerebral palsy who got Botox injections to help control spasticity in her limbs.

The US FDA said in February that Botox was being injected at an alarming rate among children, especially those who are being treated for limb spasticity associated with cerebral palsy.

It noted that neither Botox nor a similar product, Myobloc, was approved for such use in the US and said there have been deaths associated with the usage of the two treatments among children.

The FDA said in February 2008 that it knew of no deaths among adults but the class action, filed in California's Orange County Superior Court, said a 69-year-old Texas nurse and a 71-year-old woman both died after receiving Botox injections.

The nurse had been receiving injections for neck and shoulder pain, while the 71-year-old, who lived in Arizona, was taking Botox at a mall clinic for wrinkles around her mouth. The suit says she had trouble breathing and swallowing after the treatment and died a short time later.

All three of the cases involved uses of Botox that are not approved by the US FDA.The suit also charges that Botox left at least 12 other patients with a range of disabilities, including some who were taking the drug for approved uses, such as smoothing frown lines.


RBI close to softening its hawkish monetary policy: Nomura

New Delhi: Ahead of the Reserve bank of India's (RBI) 16th September monetary review, investment bank Nomura today said the central bank is likely to halt its move to raise policy rates, given the tight liquidity situation and lack of global demand, reports PTI.

"With monetary conditions tightening and global demand still sluggish, we retain our view that growth and inflation are likely to moderate in the coming quarters and that the RBI is close to pausing in its rate hiking cycle," Nomura said.

The RBI has been tightening key benchmark rates since November last year after the country started recovering from the impact of the global financial crisis.

In its last policy announcement on 27th July, the RBI raised the repo rate, at which it lends to banks, by 25 basis points to 5.75% and the reverse repo rate, at which it absorbs excess cash from the system, by 50 bps to 4.50%.

In the policy review, it had also announced that mid- quarter statements will be given out, the first of which will be done on 16th September.

The economy grew by 8.8% in the April-June quarter vis-à-vis the corresponding quarter a year ago, the fastest pace in around three years.

However, industrial growth in June has fallen to a 12-month low of 7.1% as demand cooled and the low base effect of the previous year faded away. It grew at double digits during the eight months till May.

Exports expansion, too, slowed to 13.2% in July, the lowest growth rate so far this fiscal on account of the fragile economic recovery in the US and Europe, with total shipments valued at $16.2 billion. Growth in exports was 30% in June and 35% in May.

Between FY'06 and FY'08, the economy clocked an above 9% growth. The global liquidity crisis had resulted in a slowdown in growth to 6.7% in FY'09 and 7.4% in FY'10.

Meanwhile, inflation based on wholesale prices for July fell to single-digits at 9.97% after a gap of five months, on moderating food and non-food prices, raising hopes of a sustained decline. August inflation data is due on 14th September.


We are listening!

Solve the equation and enter in the Captcha field.

To continue

Sign Up or Sign In


To continue

Sign Up or Sign In



The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)